Study		Exclusion reasons	Remarks	Reference(s)
Hersh, 2011	-	inadequate or absent control group		Hersh Invest New Drugs 2011; 29:489-98 10.1007/s10637-009-9376-8
Tarhini, 2019	-	inadequate or absent control group		Tarhini Clin. Cancer Res. 2019; 25:524-532 10.1158/1078-0432.CCR-18-2258
Wolchok, 2010	-	inadequate or absent control group		Wolchok Lancet Oncol. 2010; 11:155-64 10.1016/S1470-2045(09)70334-1 Wolchok Ann. Oncol. 2013; 24:2174-80 10.1093/annonc/mdt161
OpACIN-neo, 2019	-	not relevant outcome		Rozeman, E.A. The Lancet Oncology 2019; 20:948-. 10.1016/S1470-2045(19)30151-2